PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.
Fiche publication
Date publication
novembre 2020
Journal
Journal for immunotherapy of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier, Pr AUBIN François, Mme LAHEURTE Caroline, Dr NARDIN Charlée
Tous les auteurs :
Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, Beauvais T, Khammari A, Braudeau C, Josien R, Adotevi O, Laheurte C, Aubin F, Nardin C, Rulli S, Gottardo R, Ramchurren N, Cheever M, Fling SP, Church CD, Nghiem P, Dreno B, Riddell SR, Labarriere N
Lien Pubmed
Résumé
Clinical benefit from programmed cell death 1 receptor (PD-1) inhibitors relies on reinvigoration of endogenous antitumor immunity. Nonetheless, robust immunological markers, based on circulating immune cell subsets associated with therapeutic efficacy are yet to be validated.
Mots clés
CD8-Positive T-Lymphocytes, costimulatory and inhibitory T-Cell receptors, immunotherapy, melanoma, programmed cell death 1 receptor
Référence
J Immunother Cancer. 2020 Nov;8(2):